PGPradeep Ghimire

Pradeep Ghimire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pradeep Ghimire has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lithium toxicity: a case report

    by Ujjawal Paudel, Gajendra Bham, Prashant Raj Bhatt, Pradeep Ghimire, Aastha Parajuli, Dipesh Upreti

    Lithium is a commonly used drug for bipolar disorders and requires therapeutic dose monitoring due to its narrow therapeutic index. Acute lithium toxicity frequently occurs due to intentional intake of an excessive amount or due to its interaction with various medicines and medical conditions which alter its absorption or excretion. It may present primarily with neurological and gastrointestinal symptoms. We report a case of lithium toxicity in a patient with bipolar disorder probably due to dehydration and decreased intake of food and fluids. Frequent monitoring of serum lithium level while maintaining hydration and electrolyte balance successfully treated the lithium toxicity.


  • Open Access

    Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients

    by Anil Pokhrel, Hema Chand, Prabal K.C., Nilasma Shrestha, Pradeep Ghimire, Pravesh Ghimire, Laxman Prasad Adhikary

    Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.